<unk>  is a potassium channel opener that is FDA approved for the treatment of partial-onset seizures in patients aged 18 years and older who have responded inadequately to several alternative treatments and for whom the benefits outweigh the risk of retinal abnormalities and potential decline in visual acuity. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include dizziness, somnolence, fatigue, confusional state, vertigo, tremor, abnormal coordination, diplopia, disturbance in attention, memory impairment, asthenia, blurred vision, gait disturbance, aphasia, dysarthria, and balance disorder.
Ezogabine
Tiagabine
Retigabine
Pivagabine
Brivaracetam
Mesuximide
Ethosuximide
Methsuximide